Live meta-analysis and evidence synthesis of therapies for COVID19  

regdanvimab (CT-P59 Celltrion) vs. placebo - COVID 19 outpatients NA risk of bias

• inconclusive results for: Hospitalisation, Oxygen Therapy; hospitalization, high risk patients

risk of bias not assessable

meta-analysis

ruxolitinib vs. placebo - COVID-19 severe or critically NA risk of bias

• suggested 53 % decrease in death, all dose

risk of bias not assessable

meta-analysis

anticoagulation, intermediate prophylactic dose vs. anticoagulant, prophylactic dose - COVID-19 severe or critically some concern in risk of bias

• inconclusive results for: All-cause mortality; Major bleeding; composite of acute venous thromboembolism, arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all-cause mortality

meta-analysis

hydroxychloroquine vs. standard of care - COVID 19 outpatients some concern in risk of bias

• inconclusive results for: death; developed progressive symptoms; hospitalization

meta-analysis

azithromycin vs. standard of care - COVID-19 mild to moderate some concern in risk of bias

• inconclusive results for: In-hospital death; seven-level ordinal outcome at 15 days; six-level ordinal outcome at 7 days; use of mechanical ventilation within 15 days; serious adverse event; any adverse event; acute kidney injury within 15 days

meta-analysis

convalescent plasma treatment vs. placebo - COVID-19 severe or critically low risk of bias

• inconclusive results for: 28-day mortality; clinical status at day 28 following randomization, measured using a 7-category ordinal scale; Serious adverse events

meta-analysis

anticoagulant, curative dose vs. control - COVID-19 severe or critically some concern in risk of bias

• inconclusive results for: Death in hospital; Organ support-free days to day 21a; Major thrombotic events or death; Major bleeding

meta-analysis